Harvard Apparatus Regenerative Technology, Inc.
HRGNDrugs in Pipeline
7
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Testosterone
Hip Fracture
LACTIN-V
Bacterial Vaginosis
Folinic Acid
Autism Spectrum Disorder
Theophylline
Pseudohypoparathyroidism
glucagon
Post-bariatric Hypoglycemia
Ezogabine
Amyotrophic Lateral Sclerosis
alcohol
Type 2 Diabetes
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Testosterone | Phase 3 | Hip Fracture | - | - |
LACTIN-V | Phase 2 | Bacterial Vaginosis | - | - |
Folinic Acid | Phase 2 | Autism Spectrum Disorder | - | - |
Theophylline | Phase 2 | Pseudohypoparathyroidism | - | - |
glucagon | Phase 2 | Post-bariatric Hypoglycemia | - | - |
Ezogabine | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
alcohol | Phase 2 | Type 2 Diabetes | - | - |
Frequently asked questions
What is in Harvard Apparatus Regenerative Technology, Inc.'s drug pipeline?→
CatalystAlert tracks 7 drug candidates in Harvard Apparatus Regenerative Technology, Inc.'s (HRGN) pipeline across Phase 3, Phase 2. Its lead program is Testosterone (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Harvard Apparatus Regenerative Technology, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Harvard Apparatus Regenerative Technology, Inc. (HRGN) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track HRGN biotech catalysts?→
Add HRGN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Harvard Apparatus Regenerative Technology, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.